Serum testosterone levels and breast cancer recurrence

被引:76
作者
Berrino, F
Pasanisi, P
Bellati, C
Venturelli, E
Krogh, V
Mastroianni, A
Berselli, E
Muti, P
Secreto, G
机构
[1] Ist Nazl Tumori, Dept Prevent & Predict Med, I-20133 Milan, Italy
[2] Ist Nazl Tumori, Unit Lab Med, I-20133 Milan, Italy
[3] Ist Nazl Tumori, Dept Med, I-20133 Milan, Italy
[4] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA
关键词
breast cancer; recurrences; testosterone;
D O I
10.1002/ijc.20582
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prospective studies show that high serum levels of androgens and estrogens are associated with increased incidence of postmenopausal breast cancer. The aim of the present analysis was to study the prognostic value of serum testosterone, estradiol and related factors in postmenopausal breast cancer patients. One hundred and ten patients without clinical recurrence were included in the study. After 5.5 years of follow-up, 31 patients developed distant metastasis (16), local relapse (4), or contralateral breast cancer (11). The risk of adverse events in relation to hormone level was examined by Cox' proportional hazard modeling, adjusting for hormone receptor status and stage at diagnosis. Body mass index and serum levels of testosterone, estradiol and glucose were significantly higher in patients who recurred than those who did not. The hazard ratios were 1.8 (95 % Cl = 0.5- 6.3) for the middle and 7.2 (95% Cl = 2.4-21.4) for the upper tertiles of baseline testosterone distribution. Other hormones had only minor influence on prognosis. High testosterone predicts breast cancer recurrence. Further studies are required to determine whether dietary or other medical intervention to reduce testosterone can reduce the recurrence of breast cancer.
引用
收藏
页码:499 / 502
页数:4
相关论文
共 21 条
[1]  
[Anonymous], 1996, Lancet, V348, P1189
[2]  
Berrino F, 2002, IARC Sci Publ, V156, P439
[3]  
Berrino F, 2001, CANCER EPIDEM BIOMAR, V10, P25
[4]   WEIGHT CHANGE IN WOMEN TREATED WITH ADJUVANT THERAPY OR OBSERVED FOLLOWING MASTECTOMY FOR NODE-POSITIVE BREAST-CANCER [J].
CAMORIANO, JK ;
LOPRINZI, CL ;
INGLE, JN ;
THERNEAU, TM ;
KROOK, JE ;
VEEDER, MH .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) :1327-1334
[5]   Weight loss in breast cancer patient management [J].
Chlebowski, RT ;
Aiello, E ;
McTiernan, A .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :1128-1143
[6]  
Clarke M, 1998, LANCET, V351, P1451
[7]  
Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606
[8]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[9]   Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study [J].
Goodwin, PJ ;
Ennis, M ;
Pritchard, KI ;
Trudeau, ME ;
Koo, J ;
Madarnas, Y ;
Hartwick, W ;
Hoffman, B ;
Hood, N .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :42-51
[10]  
GRATTAROLA R, 1975, AM J OBSTET GYNECOL, V121, P169, DOI 10.1016/0002-9378(75)90633-X